SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

RBC Capital Maintains Biogen at Outperform, Raises Target to $272

RBC Capital maintained its Outperform rating on Biogen and raised its price target to $272 from $256.

BIIB

Story updates

07:30:41 PM UTC
SquawkNews
Biogen Is Maintained at Outperform by RBC Capital

Related stories